The impact of aging on antitumor immunity and cancer immunotherapy.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms and clinical considerations without systematic methodology or primary human data.
PubMed 42230256 · doi:10.1016/j.trecan.2026.05.003
What was done
This is a narrative review synthesizing literature on how biological aging remodels immune function across hematopoietic, adaptive, and innate compartments. The authors discuss mechanisms such as hematopoietic stem cell dysfunction, metabolic fitness loss, altered lymphocyte phenotypes, myeloid skewing, cellular senescence, and inflammaging, alongside patient-stratification and immune-rejuvenation approaches.
What was found
The abstract reports no numerical data or quantitative effect sizes. It qualitatively describes how age-related immune changes establish an immunosuppressive environment that impairs antitumor immunity and limits the efficacy of cancer immunotherapies in older patients.
Why it matters
As older populations face a disproportionate cancer burden, understanding age-related immune dysfunction highlights the need for age-stratified clinical approaches and adjunctive immune-rejuvenating strategies to optimize immunotherapy.
Limits
As a narrative review, the paper provides theoretical and mechanistic synthesis rather than original empirical data or systematic review analysis. The abstract reports no sample sizes, comparative effect estimates, or quantitative clinical outcomes.
Cited by
- supports Immune function declines significantly with aging, particularly in people in their 60s.